[go: up one dir, main page]

JO3322B1 - مشتقات كوينولين بصفة عوامل مضادة للبكتيريا - Google Patents

مشتقات كوينولين بصفة عوامل مضادة للبكتيريا

Info

Publication number
JO3322B1
JO3322B1 JOP/2006/0183A JOP20060183A JO3322B1 JO 3322 B1 JO3322 B1 JO 3322B1 JO P20060183 A JOP20060183 A JO P20060183A JO 3322 B1 JO3322 B1 JO 3322B1
Authority
JO
Jordan
Prior art keywords
alkyl
hydrogen
het
alkyloxy
alkylthio
Prior art date
Application number
JOP/2006/0183A
Other languages
English (en)
Inventor
Koul Anil
Emile Georges Guillemont Jerome
Francis Alain Lancois David
Jozef Lodewijk Marcel Andrise Koenraad
Madeleine Simon Motte Magali
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35447198&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3322(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of JO3322B1 publication Critical patent/JO3322B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)

Abstract

يتعلق الاختراع الحالي باستخدام مركب (compound) لتصنيع دواء (medicament) لمعالجة عدوى بكتيرية (bacterial infection) بشرط ان تكون العدوى البكترية ( bacterial infection) خلاف العدوى البكتيرية الفطرية (Mycobacterial infection) ويكون المركب المذكور هو مركب من الصيغة ( Ia) او ( Ib) : N – اوكسيد (N-oxide) منه، شكل توتومري (tautomeric form) منه او شكل ايزومري فراغي كيماوئيا (sterochemically isomeric from ) منه حيث يكون A هو ايون مضاد (counter ion)؛ R1 هو هيدروجين ( hydrogen) ، هالو ( halo) هالو الكيل ( haloalky1) ، سيانو (cyano) ، هيدروكسي (hydroxy) Ar، Het، الكيل (alky1) الكيل اوكسي (alkyloxy) ، الكيل ثيو (alkylthio) ، الكيل اوكسي الكيل ( alkyloxyalky1) الكيل ثيو الكيل (alkythioalky1) ، Ar- الكيل ( Ar- alky1) او ثنائي (Ar) الكيل (di(Ar)alky1)؛ p هو 1 الى 4؛ R2 هو هيدروجين (hydrogen) هيدروكسي (hydroxy) مركابتو (mercapto)، الكيل اوكسي (alkyloxy) الكيل اوكسي الكيل اوكسي (alkyloxyalkyloxy) الكيل ثيو (alkylthio) احادي او ثنائي (الكيل ) امينو (mono or di(alky1 )amino) او حيث يكون Y هو CH2،O،S،NH او N -الكيل (N- alky1)؛ R3 هو الكيل (alky1) ،Ar ، Ar - الكيل (Ar- alky1) ، Het او -Het الكيل (Het- alky1) ، q هو صفر الى 4؛ R4 وR5 كل منهما على حدة يكون هيدروجين (hydrogen) الكيل (alky1) او بنزيل (benzy1) او قد يؤخذ R4 و R5 معا مع ذرة N المرتبطة معهما; R6 هو هيدروجين (hydrogen) هالو ( halo) هالو الكيل ( haloalky1) ،هيدروكسي (hydroxy) ، Ar، الكيل (alky1) الكيل اوكسي (alkyloxy) ، الكيل ثيو (alkylthio) ، الكيل اوكسي الكيل ( alkyloxyalky1) الكيل ثيو الكيل (alkythioalky1) ، Ar- الكيل ( Ar- alky1) او ثنائي (Ar) الكيل (di(Ar)alky1); او قد يؤخذ شقا R6 المتجاوران معا لتشكيل CH=CH-CH=CH-; -؛ r هو 1 الى 5 R7 هو هيدروجين (hydrogen) الكيل (alky1) ،Ar او Het ؛ R8 هو هيدروجين ( hydrogen) او الكيل (alky1) : R9 هو اوكسو (OXO) او R8 و R9 معا يشكلان CH=CH-N= ؛R10 هو الكيل (alky1) الكيل كربونيل ( alkylcarbony1) ، Ar ، Ar- الكيل (Ar-alky1)، Ar كربونيل (Ar-carbony1) ، Het- الكيل (Het-alky1) او Het - كربونيل – Het carbony1`.
JOP/2006/0183A 2005-06-28 2006-06-29 مشتقات كوينولين بصفة عوامل مضادة للبكتيريا JO3322B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05105755 2005-06-28

Publications (1)

Publication Number Publication Date
JO3322B1 true JO3322B1 (ar) 2019-03-13

Family

ID=35447198

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2006/0183A JO3322B1 (ar) 2005-06-28 2006-06-29 مشتقات كوينولين بصفة عوامل مضادة للبكتيريا

Country Status (32)

Country Link
US (1) US20130030016A1 (ar)
EP (1) EP1898909B1 (ar)
JP (1) JP5193857B2 (ar)
KR (1) KR101329587B1 (ar)
CN (1) CN101252927B (ar)
AP (1) AP2547A (ar)
AR (1) AR054804A1 (ar)
AU (1) AU2006263882B2 (ar)
BR (1) BRPI0613999B8 (ar)
CA (1) CA2612614C (ar)
CY (1) CY1119402T1 (ar)
DK (1) DK1898909T3 (ar)
EA (1) EA014431B1 (ar)
ES (1) ES2610472T3 (ar)
HK (1) HK1120732A1 (ar)
HR (1) HRP20170044T1 (ar)
HU (1) HUE030264T2 (ar)
IL (1) IL188395A (ar)
JO (1) JO3322B1 (ar)
LT (1) LT1898909T (ar)
MX (1) MX2008000079A (ar)
MY (1) MY173664A (ar)
NO (1) NO341285B1 (ar)
NZ (1) NZ564340A (ar)
PL (1) PL1898909T3 (ar)
PT (1) PT1898909T (ar)
RS (1) RS55601B1 (ar)
SG (1) SG166798A1 (ar)
TW (1) TWI413520B (ar)
UA (1) UA88701C2 (ar)
WO (1) WO2007000434A1 (ar)
ZA (1) ZA200711148B (ar)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2752B1 (ar) 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
JO2970B1 (ar) 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في مشتقات الكوينولين المضادة للجراثيم
JO2683B1 (ar) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في مشتقات الكوينولين المضادة للجراثيم
JP5397881B2 (ja) * 2008-09-04 2014-01-22 昇一 城武 グラム陽性細菌用抗菌剤及び抗菌活性増強剤
DK2841425T3 (en) 2012-04-27 2016-06-27 Janssen Pharmaceutica Nv ANTIBACTERIAL QUINOLIN DERIVATIVES
JP6153603B2 (ja) 2012-04-27 2017-06-28 ヤンセン ファーマシューティカ エヌ．ベー． 抗菌性キノリン誘導体
JP7514763B2 (ja) * 2017-10-13 2024-07-11 ザ ユニバーシティー オブ クイーンズランド 亜鉛イオノフォアおよびその使用
CN110606825A (zh) * 2019-10-30 2019-12-24 成都海杰亚医药科技有限公司 一种制备吡啶-2-硫醇的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
SI2301544T1 (sl) * 2002-07-25 2013-01-31 Janssen Pharmaceutica, N.V. Derivati kinolina kot vmesne spojine za mikobakterijske inhibitorje
EP1753427B1 (en) * 2004-05-28 2008-04-02 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
EE05697B1 (et) * 2005-06-08 2014-02-17 Janssen Pharmaceutica N.V. Kinoliini derivaadid kui antibakteriaalsed toimeained

Also Published As

Publication number Publication date
WO2007000434A1 (en) 2007-01-04
EP1898909B1 (en) 2016-10-19
US20130030016A1 (en) 2013-01-31
HK1120732A1 (en) 2009-04-09
EA014431B1 (ru) 2010-12-30
AU2006263882B2 (en) 2012-12-13
PL1898909T3 (pl) 2017-03-31
BRPI0613999A2 (pt) 2011-03-01
AR054804A1 (es) 2007-07-18
ZA200711148B (en) 2013-03-27
TWI413520B (zh) 2013-11-01
NZ564340A (en) 2011-02-25
TW200800183A (en) 2008-01-01
NO341285B1 (no) 2017-10-02
UA88701C2 (ru) 2009-11-10
NO20080499L (no) 2008-02-29
CA2612614C (en) 2017-07-25
MY173664A (en) 2020-02-14
IL188395A0 (en) 2008-08-07
HRP20170044T1 (hr) 2017-03-10
EP1898909A1 (en) 2008-03-19
KR101329587B1 (ko) 2013-11-15
BRPI0613999B1 (pt) 2020-04-22
BRPI0613999B8 (pt) 2021-05-25
LT1898909T (lt) 2017-02-10
SG166798A1 (en) 2010-12-29
CN101252927B (zh) 2014-01-01
RS55601B1 (sr) 2017-06-30
AU2006263882A1 (en) 2007-01-04
HUE030264T2 (en) 2017-04-28
KR20080028459A (ko) 2008-03-31
AP2547A (en) 2012-12-26
IL188395A (en) 2012-05-31
EA200800151A1 (ru) 2008-06-30
MX2008000079A (es) 2008-03-19
JP5193857B2 (ja) 2013-05-08
ES2610472T3 (es) 2017-04-27
DK1898909T3 (en) 2017-02-06
CA2612614A1 (en) 2007-01-04
CN101252927A (zh) 2008-08-27
PT1898909T (pt) 2016-12-07
JP2008546824A (ja) 2008-12-25
CY1119402T1 (el) 2018-03-07

Similar Documents

Publication Publication Date Title
TW200744594A (en) Quinoline derivatives as antibacterial agents
TW200637551A (en) Treatment of latent tuberculosis
UA95915C2 (ru) Производные хинолина как антибактериальные средства
JO3322B1 (ar) مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
JO2837B1 (ar) مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
MY153291A (en) Quinoline derivatives as antibacterial agents
MY151030A (en) Quinoline derivatives as antibacterial agents
WO2005070924A8 (en) Substituted quinolines and their use as mycobacterial inhibitors
JO2695B1 (ar) معالجة السل الكامن